ArticleHuman vaccines & immunotherapeutics2021
The hindrances to perform the COVID-19 vaccination in Brazil.
Article in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Impact of Coronavirus Disease (COVID)-19 on the Indigenous Population of Brazil: A Systematic Review.Journal of racial and ethnic health disparities · 2026Pooled it
- COVID-19 Mortality and Temporal Trends in a Mid-Sized Southern Brazilian City (2020-2023): A Population-Based Retrospective Study.Health science reports · 2026Article
- Vaccination Coverage Against Coronavirus Disease 2019 (COVID-19) in Brazil's Indigenous Population.Journal of medical virology · 2026Article
- Vaccination Coverage Against Coronavirus Disease 2019 in People Living on Quilombos in Brazil and Its Association With the Human Development Index and the Quality of the Health System.Journal of medical virology · 2025Observational
- Demographic and Clinical Profile of Patients with Osteogenesis Imperfecta Hospitalized Due to Coronavirus Disease (COVID)-19: A Case Series of 13 Patients from Brazil.Healthcare (Basel, Switzerland) · 2025Article
- Overview of the Indigenous health of the Yanomami ethnic group in Brazil: A Public Health Emergency.Journal of racial and ethnic health disparities · 2025Article
- "Frontiers in medicine · 2025Article
- Assessment of the development of social skills among undergraduate medical students through participation in a socio-educational project during the coronavirus disease (COVID)-19 pandemic: a Brazilian pilot study.BMC medical education · 2024Observational
- Efficacy of Ivermectin, Chloroquine/Hydroxychloroquine, and Azithromycin in Managing COVID-19: A Systematic Review of Phase III Clinical Trials.Biomedicines · 2024Review
- Dynamic clade transitions and the influence of vaccination on the spatiotemporal circulation of SARS-CoV-2 variants.NPJ vaccines · 2024Article
- Article
- Vaccine coverage and effectiveness against laboratory-confirmed symptomatic and severe Covid-19 in indigenous people in Brazil: a cohort study.BMC public health · 2023Article
- Self-testing for SARS-CoV-2 in São Paulo, Brazil: results of a population-based values and attitudes survey.BMC infectious diseases · 2022Article
- Regional heterogeneity of in-hospital mortality of COVID-19 in Brazil.Infectious Disease Modelling · 2022Article
- COVID-19 Underreporting in Brazil among Patients with Severe Acute Respiratory Syndrome during the Pandemic: An Ecological Study.Diagnostics (Basel, Switzerland) · 2022Article
- The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs.BMC infectious diseases · 2022Article
- Children vaccination as a population strategy to increase COVID-19 vaccine coverage in Brazil.Lancet regional health. Americas · 2022Article
- Severe Acute Respiratory Syndrome by SARS-CoV-2 Infection or Other Etiologic Agents Among Brazilian Indigenous Population: An Observational Study from the First Year of Coronavirus Disease (COVID)-19 Pandemic.Lancet regional health. Americas · 2022Article
- How to overcome the stagnation of the first dose vaccine coverage curve against coronavirus disease 2019 in Brazil?Revista da Sociedade Brasileira de Medicina Tropical · 2022Article
- Epidemiologic Profile of Severe Acute Respiratory Infection in Brazil During the COVID-19 Pandemic: An Epidemiological Study.Frontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBrazil is one of the epicenters of COVID-19 pandemic and faces several hindrances to make his COVID-19 vaccination plan efficient.
methodsThe Brazilian COVID-19 vaccination plan was evaluated and the hindrances to make the COVID-19 vaccination plan efficient were described and discussed.
resultsHigh territorial extension might contribute to a delay on the COVID-19 vaccination, due to difficulty in delivering vaccines to furthest Brazilian states and to all the interior cities. The choice among the vaccines should be done based on the type of storage and must consider the transport conditions necessary to maintain its effectiveness. The indigenous individuals were included with health-care workers as the first group to be vaccinated, inflaming the number of vaccines doses distributed in states where the indigenous population have higher prevalence. The antivaccine movement and the politicization of the vaccine are also hindrances to be overcome in Brazil. The COVID-19 incidence or mortality rate and the distribution of intensive care units (ICUs) are not a criterion to distribute the vaccines, as we did not identify a correlation between these markers and the number of vaccines. However, a strong or very strong correlation occurred between the number of COVID-19 vaccines and the number of COVID-19 cases, deaths by COVID-19, gross domestic product, as well as populational density. A total of 83,280,475 doses of COVID-19 vaccines were distributed in Brazil. In the first dose, the Coronavac (Sinovac™), AZD1222 (AstraZeneca/Oxford™), and BNT162b (Pfizer/BioNTech™) vaccines were responsible to vaccinate, respectively, 9.61%, 6.69%, and 0.35% of the Brazilian population. In the second dose, the Coronavac, AZD1222, and BNT162b vaccines were responsible to vaccinate, respectively, 7.52%, 0.53%, and <0.01% of the Brazilian population.
conclusionsThe Federal Government must evaluate the hindrances and propose solutions to maximize the immunization against COVID-19 on Brazil.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.